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Abstract
Background: This study aimed to determine the prognostic value of positron emission tomography (PET) metabolic
parameters—namely metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion retention (TLR)—on
fluorine-18 (18F) fluorodeoxyglucose (FDG) and L- [3-18F]-α-methyltyrosine (18F-FAMT) PET/CT in patients with
non-small-cell lung cancer (NSCLC).
Methods: The study group comprised 112 NSCLC patients who underwent 18F-FDG and 18F-FAMT PET/CT
prior to any therapy. The MTV, TLG, TLR, and maximum standardized uptake value (SUVmax) of the primary
tumors were determined. Automatic MTV measurement was performed using PET volume computer assisted
reading software. (GE Healthcare). Cox proportional hazards models were built to assess the prognostic value
of MTV, TLG (for 18F-FDG), TLR (for 18F-FAMT), SUVmax, T stage, N stage, M stage, clinical stage, age, sex, tumor
histological subtype, and treatment method (surgery or other therapy) on overall survival (OS).
Results: Higher TNM, higher clinical stage, inoperable status, and higher values for all PET parameters (both
18F-FAMT and 18F-FDG PET) were significantly associated (P < 0.05) with shorter OS. Multivariate analysis
revealed that a higher MTV of 18F-FAMT (hazard ratio [HR]: 2.88, CI: 1.63–5.09, P < 0.01) and advanced clinical
stage (HR: 5.36, CI: 1.88–15.34, P < 0.01) were significant predictors of shorter OS.
Conclusions: MTV of 18F-FAMT is of prognostic value for OS in NSCLC cases and can help guide decision-making
during patient management.
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Background
Lung cancer is the leading cause of cancer-related death
worldwide for both men and women. Non-small-cell lung
cancer (NSCLC) accounts for 80% of all lung cancers [1].
Despite progress in treatment strategies, overall survival
(OS) in NSCLC remains unacceptably short—even for
early-stage disease—and progressively worsens with in-
creasing TNM stage [2, 3]. Currently, TNM stage is one of
the most important prognostic factors for NSCLC and
serves a valuable guide when choosing a treatment
strategy [3, 4]. However, TNM staging alone does not
always provide satisfactory results because each stage con-
sists of a heterogeneous population with a different risk of
relapse. Therefore, improved methods are needed to ac-
curately predict prognosis and guide treatment strategy.
Fluorine-18 (18F) fluorodeoxyglucose (FDG) positron
emission tomography (PET) is widely used for initial sta-
ging, restaging at recurrence, estimating radiotherapeutic
or chemotherapeutic responses, and delineating radio-
therapeutic targets [5–10]. The standardized uptake
value (SUV) in the NSCLC primary lesion at the time of
diagnosis is known to be an important prognostic factor
[11].
Maximum SUV (SUVmax) is a long-established value
in clinical practice for quantifying a lesion’s metabolism.
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However, as it is based on a single voxel value, SUVmax
may not represent total tumor metabolism. By contrast,
PET metabolic parameters, such as metabolic tumor vol-
ume (MTV) and total lesion glycolysis (TLG), are volu-
metric indices, and are thus more reliable reflections of
tumor burden and aggressiveness [12]. Furthermore,
these metabolic parameters are potentially useful prog-
nostic markers for various malignancies examined by
18F-FDG PET [13–16].
We have developed L-[3-18F]-α–methyltyrosine
(18F-FAMT), an amino acid PET tracer that specifically
accumulates in tumor cells via L-type amino acid trans-
porter 1 (LAT1) [17–20]. In the last two decades,
18F-FAMT has been investigated in various tumors and
shown to offer some additional clinical benefits over
18F-FDG [21, 22]. 18F-FAMT uptake within the primary
tumor, as depicted by SUVmax, is associated with poor
outcomes in NSCLC patients and is a stronger prognos-
tic factor than 18F-FDG uptake [23], making it useful for
diagnosis, staging [19], and assessment of therapeutic re-
sponse [24]. Therefore, in this study we postulated that
the metabolic tumor burden, as indicated by MTV and
total lesion retention (TLR) of 18F-FAMT, is useful as an
indicator of prognosis. The purpose of this study was to
determine the prognostic value of PET metabolic param-
eters (namely MTV, TLG, and TLR) on 18F-FDG and
18F-FAMT PET/CT in patients with NSCLC.
Methods
Patient selection
The medical records of 112 consecutive NSCLC patients
at our institution between April 2007 and August 2013
who underwent both 18F-FAMT and 18F-FDG PET/CT
before receiving any therapy were retrospectively
reviewed. Clinical and pathological TNM stages were
established using the Union Internationale Centre le
Cancer (UICC) classification. All patients agreed to par-
ticipate in this study and provided written informed con-
sent. The institutional review board approved the study
protocol. Thirteen of the 112 patients have been in-
cluded in previous reports [19, 23, 25]. These previous
articles solely evaluated SUVmax of
18F-FAMT or LAT1
expression of the tumor, whereas this study evaluated
PET metabolic parameters (MTV and TLR) and survival
prognosis.
Tracer preparation and PET scan acquisition
18F-FAMT was synthesized in our hospital cyclotron
facility according to the method developed by Tomiyoshi
et al. [17]. The radiochemical yield of 18F-FAMT was ap-
proximately 20%, with a radiochemical purity of approxi-
mately 99%. Molar activity of 18F-FAMT exceeded 0.12
GBq /μmol (3.24 Ci /mmol). 18F-FDG was also produced
in our facility as previously described [19]. Patients
fasted for at least six hours prior to 18F-FDG PET im-
aging. Patients were then injected with 5MBq/kg of
18F-FAMT or 5MBq/kg of 18F-FDG and PET acquisition
was performed one hour later. One of two PET/CT
scanners (Discovery STE 16, GE Healthcare, Milwaukee,
USA; Biograph 16 Siemens Medical Solutions, Erlangen,
Germany) was randomly selected for PET/CT acquisi-
tion. Scan parameters are shown in Table 1.
PET/CT analysis and tumor volume measurement
Two experienced nuclear medicine physicians (T.H., Y.A.)
interpreted all 18F-FAMT and 18F-FDG PET images.
Pre-existing PET data were re-analyzed for MTV, TLG, and
TLR. PET VCAR (Volume Computer Assisted Reading)
software on an Advantage Workstation (GE Healthcare,
Milwaukee, WI) was used to automatically calculate the
MTV of each lesion using SUV thresholds of 1.2 for
18F-FAMT and 2.5 for 18F-FDG. SUVmax. The average SUV
(SUVmean) within the generated 3D volume of interest
(VOI) was also calculated automatically. TLG or TLR was
defined as MTV multiplied by SUVmean. For patients with
metastases, PET parameters were determined only by their
primary tumors.
Statistical analysis
OS was defined as the time from initial PET/CT exam-
ination until patient death from any cause. For survivors,
survival time was censored at the last date that the
patient was known to be alive. Time-to-progression and
progression-free survival was not evaluated because the
times for subsequent PET imaging varied between
patients. Survival analysis was carried out using the
Kaplan-Meier method with a log-rank test to assess
Table 1 Protocol parameters for PET/CTs
parameters Discovery STE 16 Biograph
16
PET scan parameters
FOV of PET (mm) 700 × 700 700 × 700
slice thickness of PET (mm) 3.27 2.0
acquisition time (sec/bed) 120 120
bed number (bed/body) 5–6 5–6
matrix of PET (pixel) 128 × 128 128 × 128
energy window range (keV) 425–650 425–650
reconstruction 3D Iterative Reconstruction OSEM 2D
CT scan parameters
FOV of CT (mm) 500 500
slice thickness of CT (mm) 3.75 5
matrix of CT (pixel) 512 × 512 512 × 512
X-ray tube voltage (kVp) 120 120
X-ray tube current (mA) 60 400
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differences in patient survival between high and low
values of the PET parameters. The median value for
each PET parameter was employed as a cut-off in the
subsequent analysis.
Univariate and multivariate analyses were performed
using Cox proportional hazard models to identify the
independent prognostic factors for OS. The prognos-
tic factors analyzed included MTV, TLG (for
18F-FDG), TLR (for 18F-FAMT), SUVmax, T stage, N
stage, M stage, clinical stage, age, sex, tumor histo-
logical subtype, and treatment method (surgery or
other therapy). In the multivariate analysis, all vari-
ables except T stage, N stage, and M stage were in-
cluded, while the forward stepwise method was
applied to assess the potential independent effects of
prognostic factors for OS. All statistical analyses were
performed using SPSS Statistics Version 21.0 (IBM
Corp. Released 2012. Armonk, NY: IBM Corp.). A P
value of 0.05 was selected as the threshold of statis-
tical significance.
Results
The study involved 112 patients (84 males, 28 females)
with a median age of 69 years (range 32–85 years). A
summary of patient and tumor characteristics is pre-
sented in Table 2. The median time interval between
18F-FDG PET and 18F-FAMT PET was 3 days (mean, 5.8;
range, 1–32 days). Seventy patients underwent 18F-FDG
PET prior to 18F-FAMT PET (70/112 cases, 62.5%),
while 42 patients underwent 18F-FAMT PET before
18F-FDG PET. The median SUVmax, MTV, and TLR (or
TLG) values were 2.0, 7.0 cm3, and 10.7 for 18F-FAMT
and 9.7, 25.9 cm3, and 127.0 for 18F-FDG, respectively.
The median follow-up duration at the end of the study
was 575.5 days. Fifty-five patients (49%) were alive at the
end of the follow-up period. All PET parameters of both
radiotracers significantly differentiated patient OS based
on the respective cut-off values (Figs. 1, 2 and 3). Pa-
tients with larger MTV had a significantly shorter me-
dian OS than those with smaller MTV on both
18F-FAMT (507 days vs. 2352 days) (Fig. 1a) and
18F-FDG (792 days vs. 1075 days) (Fig. 1b).
In the univariate Cox proportional hazard model ana-
lyses, a higher TNM, higher clinical stage, inoperable sta-
tus, and higher values for all 18F-FAMT and 18F-FDG PET
parameters were significantly associated with shorter OS
(P < 0.05). Older age, male sex, and adenocarcinoma sub-
types were not associated with shorter OS. However, when
all factors except T stage, N stage, and M stage were in-
cluded in the forward stepwise multivariate Cox propor-
tional hazard model, two independent significant
prognostic factors of OS remained: MTV of 18F-FAMT
(hazard ratio [HR]: 2.88, CI: 1.63–5.09, P < 0.01) and clin-
ical stage (HR: 5.36, CI: 1.88–15.34, P < 0.01). The results
of the univariate and multivariate analyses of factors
affecting OS are summarized in Table 3.
Discussion
In the present study, MTV of 18F-FAMT was found to
be highly prognostic of OS in NSCLC cases, regardless
of tumor subtype and stage. The clinical stage remained
as an independent prognostic factor of OS along with
MTV. Previous meta-analysis has shown that 18F-FDG
uptake, as represented by SUVmax, in the primary tu-
mors of NSCLC patients, is an independent prognostic
factor for survival [11]. However, in this study, SUVmax
of 18F-FAMT and 18F-FDG was not an independent
prognostic factor of OS. One possibility for this result is
that when a tumor reaches an advanced stage, SUVmax,
which is a single voxel representation, is no longer
prognostic.
Several studies have found that the volumetric param-
eter is potentially a better predictor of outcome than
SUVmax [26–28]. We confirmed that MTV and TLG of
18F-FDG failed to serve as independent prognostic factors
for NSCLC cases, although recent studies [15, 28–30] and
a meta-analysis [12] suggest otherwise. The heterogeneity
of the patient populations and different methods used to
obtain MTV values might account for this discrepancy.
Interestingly, we also found that TLR was not an inde-
pendent prognostic factor, whereas MTV of 18F-FAMT
remained significant. This result may relate to the fact that
SUVmean of
18F-FAMT is typically low and TLR, defined
Table 2 Summary of Patients Characteristics
Variable All patients (n = 112)




Histologic subtype, n (%)
Adenocarcinoma 72 (64.3%)
Squamous cell carcinoma 28 (25.0%)
Other 12 (10.7%)
TNM stage
T1/T2/T3/T4 25 / 47 / 10 / 30
N0/N1/N2/N3 29 / 13 / 41 / 29
M0/M1 63 / 49





Surgery + Chemotherapy 8 (7.1%)
aNumbers in parentheses are ranges
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as MTV multiplied by SUVmean, might underestimate the
tumor volume.
This study mainly examined the prognostic potential
of MTV and TLR of 18F-FAMT, a tumor-specific PET
radiotracer. Representative patient images, as shown in
Figs. 4 and 5, suggest that 18F-FAMT uptake represents
malignancy more accurately than 18F-FDG uptake, based
on patient OS. Our results suggest that MTV of
18F-FAMT might have an advantage over MTV of
18F-FDG, whereas the independent prognostic value of
SUVmax for both radiotracers remains questionable.
MTV and TLG of 18F-FDG have been evaluated in vari-
ous tumors within the last decade and found to have po-
tential for treatment evaluation or as a prognostic tool
[31, 32]. However, 18F-FDG has inherent limitations; for
instance, physiological uptake and inflammatory uptake
Fig. 1 Overall survival of NSCLC patients according to the MTV of 18F-FAMT (a) and 18F-FDG (b)
Fig. 3 Overall survival of NSCLC patients according to the SUVmax of
18F-FAMT (a) and 18F-FDG (b)
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Fig. 2 Overall survival of NSCLC patients according to the TLR of 18F-FAMT (a) and TLG of 18F-FDG (b)
Table 3 Cox proportional Hazard model analysis of potential prognostic factors influencing Os
parameters Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) p value Hazard Ratio (95% CI) p value
Patient
age (69 vs < 69) 1.17 (0.69, 1.96) 0.57
sex (Male vs Female) 1.44 (0.76, 2.73) 0.26
Histologic subtype
adenocarcinoma vs others 0.80 (0.47, 1.37) 0.42
TNM stage
T stage (T3/4 vs T1/2) 2.57 (1.49, 4.44) < 0.01
N stage (N2/3 vs N0/1) 1.84 (1.03, 3.25) < 0.05
M stage (M1 vs M0) 2.20 (1.28, 3.77) < 0.01
Clinical stage
III/IV vs I/II 5.92 (2.08, 16.80) < 0.01 5.36 (1.88, 15.34) < 0.01
Treatment
inoperable vs operable 5.37 (2.31, 12.45) < 0.01
18F-FDG PET parameters
SUVmax (9.7 vs < 9.7) 2.24 (1.29, 3.88) < 0.01
MTV (cm3) (25.9 vs < 25.9) 1.81 (1.06, 3.08) < 0.05
TLG (127.0 vs < 127.0) 2.03 (1.19, 3.48) < 0.05
18F-FAMT PET parameters
SUVmax (2.0 vs < 2.0) 2.17 (1.26, 3.74) < 0.01
MTV (cm3) (7.0 vs < 7.0) 3.14 (1.79, 5.53) < 0.01 2.88 (1.63, 5.09) < 0.01
TLR (10.7 vs < 10.7) 2.78 (1.59, 4.87) < 0.01
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may complicate tumor delineation and, in turn, the con-
struction of MTV. The considerable time and effort
required to produce MTV—especially if using the man-
ual method—preclude these metabolic parameters from
entering daily clinical practice. However, several auto-
mated 3D VOI generating software packages have re-
cently been developed to address this challenge [31–33].
The availability of tumor-specific PET radiotracers
multiplies the benefits of these metabolic parameters.
The present study is the first to evaluate the prognostic
value of MTV and TLR on pretreatment 18F-FAMT
PET/CT in patients with NSCLC. Previous reports have
shown the advantage of MTV of 18F-FAMT for tumor
delineation for accurate volume prediction [21, 34]. In-
deed, we found that MTV of 18F-FAMT was useful for
prognostic purposes.
However, our study had several limitations. The first is
the predefined threshold method for delineation of le-
sion edges; this threshold choice greatly influenced the
measurement of MTV, TLG, and TLR. The threshold of
SUV 2.5 for 18F-FDG was chosen because it is widely
used for tumor delineation [12]. For 18F-FAMT in
NSCLC lesions, this was the first study to comprise
tumor volume rather than a single-pixel SUVmax value.
Thus, we investigated thresholds from SUV 1.2 to 1.8 in
a smaller number of patients in advance to determine
the optimum threshold for 18F-FAMT; SUV 1.2 was
found to be optimal for generating a 3D VOI that cov-
ered the whole tumor mass in all cases. Second, patients
were examined using two different PET/CT scanners.
Second, the patients were examined with two different
PET/CT scanners. This might have affected the quantita-
tive accuracy of PET data. However, both scanners are
routinely cross-calibrated to ensure the comparability of
SUV in our hospital. Third, actual tumor uptake of
18F-FAMT was relatively low relative to that of 18F-FDG
[35]. Low uptake may induce false-negative findings if it
is used as a single tool for NSCLC staging. However, at
our hospital, 18F-FAMT PET/CT studies are always per-
formed along with 18F-FDG PET/CT. We believe that
18F-FAMT PET/CT can provide additional information
to what 18F-FDG PET/CT provides. Since molecular
targeting therapy needs additional information on amino
acid metabolism, 18F-FAMT PET/CT can provide im-
portant information for predicting therapeutic effects.
Fourth, only primary tumors were evaluated in patients
with metastases. Metabolic information about metastatic
tumors may be of additional prognostic value. Thus,
MTV, TLG, and TLR may have been underestimated in
some cases; however, MTV of 18F-FAMT was proven to
be a good prognostic indicator. We presumed that meta-
bolic information about metastatic tumors might be in-
sufficient to interfere with the prognostic value of MTV
of 18F-FAMT. Fifth, this study involved a relatively small
Fig. 4 PET images of a 60-year-old male NSCLC patient at stage IIIB (T4N0M0) with high 18F-FAMT uptake (SUVmax = 3.6, MTV = 166.0 cm
3, TLR = 315.4)
(a, b) and high 18F-FDG uptake (SUVmax = 14.8, MTV = 209.0 cm
3, TLG = 1442.1) (c, d). This patient was treated with chemotherapy and died 122 days later
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number of patients with heterogeneous characteristics at
clinical stage I to IV. A study with a larger number of
patients is required to further validate our results.
Conclusion
The MTV of 18F-FAMT was found to be an independent
risk factor and may be a better predictor of OS than
18F-FDG in NSCLC cases. Thus, the MTV of 18F-FAMT
could be valuable for guiding decision-making during
NSCLC patient management.
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